Table 1.

Patient and study characteristics summarized by study [reference]

	Study 1 [50]	Study 2 [18]	Study 3 [17]	Study 4 [19]	Study 5 [13]	Study 6 [16]	Study 7 [14]
Number of patients	14	1091	25	172	25	27	97
Number of patients included	11	129	7	14	25	26	46
Number of samples
Pregnant	110	NA	NA	NA	224	317	123
Not pregnant	109	541	77	23	199	199	46
Median gestational age at sampling times, years (range)	34 (32–36)	NA	NA	NA	34 (29–38)	29 (21–37)	37 (33–39)
Sampling design (hours postdose)	Rich crossover: 0 (predose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24	Sparse: mid-dose	Rich: 0 (predose), 1, 2, 3, 4, 6, 8, 10, 12, 16, 24	Sparse: mid-dose	Rich crossover: 0 (predose), 1, 2, 4, 6, 8, 12, 24	Rich crossover: 0 (predose), 1, 2, 4, 6, 8, 12, 24	Sparse crossover: mid-dose
Lower limit of quantification (mg/L)	0.05	0.05	0.05	0.01	0.03	0.03	0.02
Median weight (range)
Second trimester	NA	NA	NA	NA	78 (69–89) [n = 3]	83 (54–129) [n = 14]	NA
Third trimester	69 (45–124) [n = 11]	NA	NA	NA	69 (40–130) [n = 25]	80 (55–128) [n = 25]	72 (52–112) [n = 33]
Not pregnant	76 (50–132) [n = 11]	60 (40–100)	53 (46–64)	60 (49–71)	63 (37–125) [n = 25]	74 (47–126) [n = 26]	67 (42–105) [n = 39]
CYP2B6 phenotype	Not determined	Not determined	Not determined	Not determined	Not determined	Not determined	1 not determined
Poor metabolizer							10
Intermediate metabolizer							25
Extensive metabolizer							26
Efavirenz dose, mg	600	600	600	600 (300 mg, n = 1; 400 mg, n = 1)	600 (800 mg, n = 3)	600	600
Population	100% Black	Mixed international (Thailand, South Africa, South America, Western Countries)	100% Black	100% Caucasian	84% Thai, 16% Caucasian	56% Hispanic, 4% unknown, 40% non-Hispanic	100% Black

NA not available, CYP cytochrome P450